Merck Sharp AND Dohme has 18 drugs losing patent protection between 2026 and 2031 in this data. The nearest is Juvisync (simvastatin; sitagliptin phosphate) on October 11, 2026; the company listed 12 patents on it with the FDA, and that is the last one to expire.
This is the earliest date a generic could enter; it is not a guarantee one will. We calculate it as the later of the last patent the company listed with the FDA and the last regulatory exclusivity. Companies often reach settlement agreements with generic makers for a different date, and those agreements are not public in this data.
Juvisync (simvastatin; sitagliptin phosphate)Merck Sharp AND Dohme · 12 patents · October 11, 2026
Janumet XR (metformin hydrochloride; sitagliptin pho)Merck Sharp AND Dohme · 6 patents · May 24, 2027
Januvia (sitagliptin phosphate)Merck Sharp AND Dohme · 6 patents · May 24, 2027
Emend (aprepitant)Merck Sharp AND Dohme · 6 patents · September 26, 2027
Emend (aprepitant)Merck Sharp AND Dohme · 1 patent · September 26, 2027
Victrelis (boceprevir)Merck Sharp AND Dohme · 2 patents · November 11, 2027
Zolinza (vorinostat)Merck Sharp AND Dohme · 3 patents · March 18, 2028
Bridion (sugammadex sodium)Merck Sharp AND Dohme · 4 patents · June 12, 2028
Janumet (metformin hydrochloride; sitagliptin pho)Merck Sharp AND Dohme · 8 patents · January 21, 2029
Isentress (raltegravir potassium)Merck Sharp AND Dohme · 2 patents · September 11, 2029
Dutrebis (lamivudine; raltegravir potassium)Merck Sharp AND Dohme · 2 patents · September 11, 2029
Isentress (raltegravir potassium)Merck Sharp AND Dohme · 5 patents · June 2, 2030
Zepatier (elbasvir; grazoprevir)Merck Sharp AND Dohme · 2 patents · May 4, 2031
Prevymis (letermovir)Merck Sharp AND Dohme · 2 patents · August 30, 2031
Prevymis (letermovir)Merck Sharp AND Dohme · 2 patents · August 30, 2031
Segluromet (ertugliflozin; metformin hydrochloride)Merck Sharp AND Dohme · 12 patents · December 19, 2031
Steglatro (ertugliflozin)Merck Sharp AND Dohme · 2 patents · December 19, 2031
Steglujan (ertugliflozin; sitagliptin phosphate)Merck Sharp AND Dohme · 10 patents · December 19, 2031
Questions
How many Merck Sharp AND Dohme drugs lose patent protection between 2026 and 2031?
18 Merck Sharp AND Dohme drugs lose patent protection between 2026 and 2031 in this data.
What is Merck Sharp AND Dohme's nearest patent expiration?
Juvisync (simvastatin; sitagliptin phosphate) on October 11, 2026; the company listed 12 patents on it with the FDA.
Dates from the FDA Orange Book, the official record of which patents cover
which approved drug; updated monthly. Facts only, not investment advice. Verify against the
Orange Book and primary filings. pdufa.bio is not affiliated with the FDA.
Not affiliated with or endorsed by the FDA. pdufa.bio is an independent publication with no affiliation with, endorsement by, sponsorship by, or connection to the U.S. Food and Drug Administration or any other government agency. “FDA”, “PDUFA” and all company, drug and ticker names are used descriptively and remain the property of their respective owners.
Informational and educational purposes only. Not investment advice. Nothing on this page is investment, legal, tax or medical advice, or an offer or solicitation to buy or sell any security. pdufa.bio is not a registered investment adviser or broker-dealer and does not recommend trades or publish individual-drug approval probabilities. Verify every date and outcome against primary FDA, SEC or company filings. Data is provided as is, without warranty of any kind, and past behaviour does not predict future outcomes.